Medytox Solutions, Inc. 4
4 · Medytox Solutions, Inc. · Filed Nov 12, 2015
Insider Transaction Report
Form 4
Mendolia Thomas Francis DO
CEO of Company Laboratories10% Owner
Transactions
- Disposition to Issuer
Options to Purchase Common Stock
2015-11-02−1,000,000→ 0 totalExercise: $5.00From: 2012-10-01Exp: 2017-12-31→ Common Stock (1,000,000 underlying) - Disposition to Issuer
Options to Purchase Common Stock
2015-11-02−1,000,000→ 0 totalExercise: $10.00From: 2012-10-01Exp: 2022-12-31→ Common Stock (1,000,000 underlying) - Disposition to Issuer
Common Stock
2015-11-02−4,530,000→ 0 total - Disposition to Issuer
Series B Preferred Stock
2015-11-02−1,000→ 0 total - Disposition to Issuer
Options to Purchase Common Stock
2015-11-02−1,000,000→ 0 totalExercise: $2.50From: 2012-10-01Exp: 2017-12-31→ Common Stock (1,000,000 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to merger agreement among Medytox Solutions, Inc. ("Medytox"), CollabRx Merger Sub, Inc. ("Merger Sub"), and Rennova Health, Inc. ("Rennova") (f/k/a/ CollabRx, Inc.) in exchange for 1,855,659 shares of Rennova common stock.
- [F2]Disposed of pursuant to merger agreement among Medytox, Merger Sub and Rennova in exchange for 1,000 shares of Rennova Series B Convertible Preferred Stock.
- [F3]Cancelled pursuant to merger agreement and related transactions between Medytox and Rennova.